Sensipar®

DRUG2 trials

Sponsors

Amgen

Conditions

NephrologySecondary Hyperparathyroidism

Phase 4

ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism

CompletedNCT00135304

AmgenSecondary Hyperparathyroidism

Start: 2005-08-31End: 2006-12-31Updated: 2014-02-11

Unknown Phase

A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)

CompletedNCT00189501

AmgenNephrology

Start: 2004-12-31Target: 1000Updated: 2007-12-28